USE OF AN IL-6/IL-6 RECEPTOR COMPLEX FOR PREVENTING XEROSTOMIA INDUCED BY RADIOTHERAPY OR CHEMOTHERAPY

(19)

(11)

EP 2 217 264 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	27.02.2013 Bulletin 2013/09

(45)	Mention of the grant of the patent:
	16.01.2013 Bulletin 2013/03

(21)	Application number: 08853559.6

(22)	Date of filing: 27.11.2008

(51)

International Patent Classification (IPC):

A61K 38/20^(2006.01)
A61K 35/00^(2006.01)
A61K 48/00^(2006.01)

C07K 14/54^(2006.01)
A61P 1/00^(2006.01)
A61K 38/17^(2006.01)

(86)	International application number:
	PCT/IL2008/001556

(87)	International publication number:
	WO 2009/069133 (04.06.2009 Gazette 2009/23)

(54)

USE OF AN IL-6/IL-6 RECEPTOR COMPLEX FOR PREVENTING XEROSTOMIA INDUCED BY RADIOTHERAPY OR CHEMOTHERAPY

VERWENDUNG EINES IL-6/IL-6 REZEPTOR KOMPLEX ZUR VORBEUGUNG VON CHEMOTHERAPIE- ODER RADIOTHERAPIE-VERURSACHTER XEROSTOMIE

UTILISATION D'UN COMPLEXE iIL-6/RÉCEPTEUR D'IL-6 POUR PRÖVENIR LA XÉROSTOMIE INDUITE PAR LA RADIOTHÉRAPIE OU LA CHIMIOTHÉRAPIE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

28.11.2007 US 990631 P

(43)	Date of publication of application:
	18.08.2010 Bulletin 2010/33

(73)	Proprietors:
	Hadasit Medical Research Services and Development Ltd. 91120 Jerusalem (IL) Christian-Albrechts-Universität zu Kiel 24118 Kiel (DE)

(72)	Inventors:
	AXELROD, Jonathan H. 93510 Jerusalem (IL) GALUN, Eithan 90836 Har-Adar (IL) ROSE-JOHN, Stefan D-24211 Schellhorn (DE) MARMARY, Itzhack 90820 Motza Ilit (IL)

(74)	Representative: Becker Kurig Straus
	Bavariastrasse 7 80336 München 80336 München (DE)

(56)

References cited: :

EP-A1- 1 598 364
WO-A2-03/092579
US-A- 5 171 840
US-A- 6 054 294

WO-A1-2005/105135
WO-A2-2006/134601
US-A- 5 994 409
US-A1- 2004 157 326

DATABASE WPI Week 200708 Thomson Scientific, London, GB; AN 2007-083150 XP002661758, & WO 2006/116948 A1 (CHENGDU BIOLOGICAL PROD GRADUATE SCHOOL) 9 November 2006 (2006-11-09)
JONES S A ET AL: "The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1592, no. 3, 11 November 2002 (2002-11-11), pages 251-263, XP004391604, ISSN: 0167-4889, DOI: 10.1016/S0167-4889(02)00319-1
NAGLER RAFAEL M: "Effects of radiotherapy and chemotherapeutic cytokines on a human salivary cell line", ANTICANCER RESEARCH, vol. 18, no. 1A, January 1998 (1998-01), pages 309-314, XP009153340, ISSN: 0250-7005
FISCHER ET AL.: 'A bioactive designer cytokine for human hematopoietic progenitor cell expansion' NATURE BIOTECHNOLOGY vol. 15, February 1997, pages 142 - 145, XP002279305

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).